March 8, 2017 06:26 AM ESTUpdated 10:47 AM

Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition

John Carroll

Editor & Founder

The German aerosol therapy company PARI Pharmaceuticals is spinning out a Phase III effort to develop a drug/device combo that matches an inhaled formulation of …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Biotech spin­out grabs $46M round, jumps straight in­to PhI­II with a drug/de­vice com­bo for rare lung con­di­tion

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Biotech spinout grabs $46M round, jumps straight into PhIII with a drug/device combo for rare lung condition